1700 NEW CONCEPTS FOR ELECTROMOTIVE DRUGS ADMINISTRATION IN PEYRONIE'S DISEASE PATIENTS

Abstract

You have accessJournal of UrologySexual Function/Dysfunction/Andrology: Peyronie's Disease/Surgical Therapy I1 Apr 20121700 NEW CONCEPTS FOR ELECTROMOTIVE DRUGS ADMINISTRATION IN PEYRONIE'S DISEASE PATIENTS Marco Grasso, Salvatore Blanco, Caterina Lania, Francesco Antomarchi, and Angelica Grasso Marco GrassoMarco Grasso Monza, Italy More articles by this author , Salvatore BlancoSalvatore Blanco Monza, Italy More articles by this author , Caterina LaniaCaterina Lania Milano, Italy More articles by this author , Francesco AntomarchiFrancesco Antomarchi Monza, Italy More articles by this author , and Angelica GrassoAngelica Grasso Milano, Italy More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2012.02.1595AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES At the current state there is no gold standard therapy for the treatment of Peyronie's disease in patients not candidates for surgical management. Numerous studies with controversial conclusions regarding medications or physical therapy are available. Transdermal drug delivery using verapamil via electromotive drug administration (EMDA) has been proposed as an alternative to intralesional administration that has proven to be not feasible. Objective of this study is to evaluate the results of a new method of administration of verapamil which provides both a subcutaneous and transdermal administration with EMDA. METHODS A total of 54 patients were considered for this study. All patients (aged between 36 and 71 years) were suffering from Peyronie's disease. Was taken into account position number and size of plaques, stretched penile length, measurement of curvature of the penis in erection. All patients reported sexual activity preserved but reduced in frequency of intercourse and satisfaction. Division of patients: 28 patients referred to the center 1 (group 1) were subjected to transdermal administration of 4 mg of verapamil in 4cc of saline via EMDA using a Mini-Physionizer (Physion, Mirandola, Italy) synchroneous with subcutaneus perilesional administration of 1mg of verapamil twice a week for a month; (group 2) 26 patients referred to the center 2 were treated with daily oral administration of 30mg of vitamine E and 10mg of paraaminobenzoic acid. Patients has been revaluated at the end of treatment. RESULTS In the two study groups, there are not significant differences in age, number and size of plaques, disease duration and degree of curvature. Group 1: 19 patients have improved in frequency of intercourse and satisfaction, 7 showed no change, 2 fared worse. Group 2: 5 patients have improved in frequency of intercourse and satisfaction, 12 showed no change, 9 fared worse. Odds ratio 8.8 for group. CONCLUSIONS Further studies are needed to determine whether verapamil administered via subcutaneous and EMDA are effective in the treatment of Peyronie's disease. In our opinion is very important to supply a quantity of drug over the skin because it is the main diffusion barrier. We believe that a randomized study would be ideal to demonstrate the effectiveness of the therapy, but is ethically questionable to exclude a well-defined patient group from a recommended therapy. We used a criterion that we call “sliding doors”, a comparison between patients with the same characteristics referred to Centers where different treatments for the same disease are perormed. © 2012 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 187Issue 4SApril 2012Page: e686 Advertisement Copyright & Permissions© 2012 by American Urological Association Education and Research, Inc.MetricsAuthor Information Marco Grasso Monza, Italy More articles by this author Salvatore Blanco Monza, Italy More articles by this author Caterina Lania Milano, Italy More articles by this author Francesco Antomarchi Monza, Italy More articles by this author Angelica Grasso Milano, Italy More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...